Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

358
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
358
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving01:29

Mechanistic Models: Compartment Models in Algorithms for Numerical Problem Solving

48
Mechanistic models play a crucial role in algorithms for numerical problem-solving, particularly in nonlinear mixed effects modeling (NMEM). These models aim to minimize specific objective functions by evaluating various parameter estimates, leading to the development of systematic algorithms. In some cases, linearization techniques approximate the model using linear equations.
In individual population analyses, different algorithms are employed, such as Cauchy's method, which uses a...
48

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of healthy lifestyle with incident cardiovascular diseases in individuals with type 1 diabetes mellitus: a prospective cohort study.

Diabetology & metabolic syndrome·2026
Same author

Integrated anthropometric correlates of planned change-of-direction performance (T-test) in male badminton players: a partial least squares regression study.

Frontiers in physiology·2026
Same author

Concurrent control of natural and robotic limbs through a tactile-encoded brain-computer interface.

Nature communications·2026
Same author

Jasmonate, salicylate, and ethylene-responsive transcriptomics discovery in spikelets of three wheat genotypes reveals a rapid and conserved response for jasmonate signaling.

Plant signaling & behavior·2026
Same author

Assessing different Protein A resins' homodimer separation potentials through processing a two-antibody-containing artificial mixture.

Protein expression and purification·2026
Same author

Reply to "Letter to the editor: methodological considerations in the benchmarking of AI-based protein-aptamer complex prediction".

Briefings in bioinformatics·2026

Related Experiment Video

Updated: Jun 24, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K

Integrating transformers and many-objective optimization for drug design.

Nicholas Aksamit1, Jinqiang Hou2,3, Yifeng Li4,5

  • 1Department of Computer Science, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, ON, L2S 3A1, Canada.

BMC Bioinformatics
|June 7, 2024
PubMed
Summary

This study introduces a novel AI framework for drug design, integrating Transformer models and many-objective optimization. It effectively identifies drug candidates with high binding affinity, low toxicity, and good drug-likeness for cancer-related targets.

Keywords:
ADMETDrug designEvolutionary algorithmLPA1Many-objective optimizationMolecular generationParticle swarm optimizationTransformers

More Related Videos

Optimization of Synthetic Proteins: Identification of Interpositional Dependencies Indicating Structurally and/or Functionally Linked Residues
07:08

Optimization of Synthetic Proteins: Identification of Interpositional Dependencies Indicating Structurally and/or Functionally Linked Residues

Published on: July 14, 2015

7.3K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.5K

Related Experiment Videos

Last Updated: Jun 24, 2025

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.0K
Optimization of Synthetic Proteins: Identification of Interpositional Dependencies Indicating Structurally and/or Functionally Linked Residues
07:08

Optimization of Synthetic Proteins: Identification of Interpositional Dependencies Indicating Structurally and/or Functionally Linked Residues

Published on: July 14, 2015

7.3K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.5K

Area of Science:

  • Computational chemistry and artificial intelligence in drug discovery.

Background:

  • Drug design requires novel molecules targeting specific proteins, a complex process.
  • Artificial intelligence (AI) shows promise in accelerating drug design but often faces limitations with multiple objectives.
  • Existing multi-objective approaches restrict the number of optimization goals.

Purpose of the Study:

  • To develop a novel AI framework for drug design from a many-objective perspective.
  • To integrate advanced molecular generation models with comprehensive drug design predictions and optimization techniques.
  • To explore the efficacy of Transformer-based models and many-objective metaheuristics in identifying effective drug candidates.

Main Methods:

  • A framework combining a latent Transformer model (ReLSO or FragNet) for molecular generation.
  • Integration of absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, molecular docking, and many-objective metaheuristics.
  • Comparative analysis of ReLSO and FragNet for molecular generation performance.
  • Evaluation of six many-objective metaheuristics on a drug design task targeting human lysophosphatidic acid receptor 1.

Main Results:

  • ReLSO demonstrated superior performance over FragNet in molecular reconstruction and latent space organization.
  • The study identified a multi-objective evolutionary algorithm based on dominance and decomposition as the most effective.
  • This algorithm successfully found molecules with high binding affinity, low toxicity, and high drug-likeness.

Conclusions:

  • The proposed framework effectively combines Transformer models with many-objective computational intelligence for advanced drug design.
  • The findings highlight the potential of this integrated approach for discovering potent and safe drug candidates.
  • This research advances the field by enabling optimization across a greater number of critical drug design objectives.